These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26209688)

  • 21. The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ..
    Gnant M; Eidtmann H
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S2-6. PubMed ID: 20427029
    [No Abstract]   [Full Text] [Related]  

  • 22. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Berruti A; Buttigliero C; Dogliotti L
    N Engl J Med; 2009 May; 360(22):2368; author reply 2369-70. PubMed ID: 19484817
    [No Abstract]   [Full Text] [Related]  

  • 23. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
    Gnant M
    Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone- and chemotherapy-induced bone loss in breast cancer.
    Coleman RE
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
    Jonat W
    MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant bisphosphonates: a new standard of care?
    Gnant M
    Curr Opin Oncol; 2012 Nov; 24(6):635-42. PubMed ID: 23042123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone health after diagnosis of breast cancer.
    Ruzycki SM; Nixon NA
    CMAJ; 2018 Dec; 190(49):E1452. PubMed ID: 30530612
    [No Abstract]   [Full Text] [Related]  

  • 31. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
    Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
    Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?
    Dhesy-Thind SK
    J Clin Oncol; 2012 May; 30(13):1408-10. PubMed ID: 22370320
    [No Abstract]   [Full Text] [Related]  

  • 34. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biphosphonates in breast cancer--based on a Cochrane meta-analysis].
    Junker N; Nielsen DL; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3108-11. PubMed ID: 17877961
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effects of zoledronic acid in the treatment of breast cancer].
    Chen J; Liu ZY; Zhao LJ
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
    [No Abstract]   [Full Text] [Related]  

  • 37. Does zoledronic acid have additive effect on suppression of plasma estrogen levels?
    Sendur MA; Aksoy S; Ozdemir NY; Akinci MB; Zengin N; Altundag K
    Asian Pac J Cancer Prev; 2013; 14(1):607-8. PubMed ID: 23534804
    [No Abstract]   [Full Text] [Related]  

  • 38. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
    Costa L
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone targeted therapies in early breast cancer.
    Tabane K; Vorobiof DA
    Curr Treat Options Oncol; 2011 Dec; 12(4):412-23. PubMed ID: 21887503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.
    Brufsky AM
    Curr Oncol Rep; 2008 Jan; 10(1):18-26. PubMed ID: 18366957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.